Karolinska Development AB ser. B (ST:KDEV) — Market Cap & Net Worth
Market Cap & Net Worth: Karolinska Development AB ser. B (KDEV)
Karolinska Development AB ser. B (ST:KDEV) has a market capitalization of $29.36 Million (Skr272.85 Million) as of June 19, 2026. Listed on the ST stock exchange, this Sweden-based company holds position #23886 globally and #465 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Karolinska Development AB ser. B's stock price Skr0.29 by its total outstanding shares 942472033 (942.47 Million). Review total liabilities of Karolinska Development AB ser. B to assess the company's total debt and financial obligations.
Karolinska Development AB ser. B Market Cap History: 2015 to 2026
Karolinska Development AB ser. B's market capitalization history from 2015 to 2026. Data shows change from $973.68 Million to $29.36 Million (-28.88% CAGR).
Karolinska Development AB ser. B Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Karolinska Development AB ser. B's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
4.09x
Karolinska Development AB ser. B's market cap is 4.09 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $608.55 Million | $5.36 Million | -$216.83 Million | 113.54x | N/A |
| 2017 | $583.19 Million | $2.46 Million | $179.59 Million | 236.69x | 3.25x |
| 2018 | $630.86 Million | $3.07 Million | $30.51 Million | 205.29x | 20.68x |
| 2019 | $358.03 Million | $3.38 Million | $657.71 Million | 105.80x | 0.54x |
| 2020 | $182.57 Million | $2.65 Million | -$385.48 Million | 68.87x | N/A |
| 2021 | $539.58 Million | $2.17 Million | $353.85 Million | 248.65x | 1.52x |
| 2022 | $175.47 Million | $2.30 Million | -$145.04 Million | 76.29x | N/A |
| 2023 | $172.22 Million | $2.01 Million | $5.39 Million | 85.51x | 31.98x |
| 2024 | $96.66 Million | $1.84 Million | -$8.10 Million | 52.59x | N/A |
| 2025 | $44.22 Million | $10.80 Million | -$193.85 Million | 4.09x | N/A |
Competitor Companies of KDEV by Market Capitalization
Companies near Karolinska Development AB ser. B in the global market cap rankings as of June 19, 2026.
Key companies related to Karolinska Development AB ser. B by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #221 globally with a market cap of $110.45 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #445 globally with a market cap of $62.84 Billion USD.
- UCB SA (BR:UCB): Ranked #547 globally with a market cap of $49.68 Billion USD ( €42.50 Billion EUR).
- Argen-X (BR:ARGX): Ranked #573 globally with a market cap of $47.14 Billion USD ( €40.32 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #221 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $110.45 Billion | $451.63 |
| #445 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $62.84 Billion | $609.94 |
| #547 | UCB SA | BR:UCB | $49.68 Billion | €249.20 |
| #573 | Argen-X | BR:ARGX | $47.14 Billion | €762.80 |
Karolinska Development AB ser. B Historical Marketcap From 2015 to 2026
Between 2015 and today, Karolinska Development AB ser. B's market cap moved from $973.68 Million to $ 29.36 Million, with a yearly change of -28.88%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | Skr29.36 Million | -33.60% |
| 2025 | Skr44.22 Million | -54.25% |
| 2024 | Skr96.66 Million | -43.88% |
| 2023 | Skr172.22 Million | -1.85% |
| 2022 | Skr175.47 Million | -67.48% |
| 2021 | Skr539.58 Million | +195.56% |
| 2020 | Skr182.57 Million | -49.01% |
| 2019 | Skr358.03 Million | -43.25% |
| 2018 | Skr630.86 Million | +8.17% |
| 2017 | Skr583.19 Million | -4.17% |
| 2016 | Skr608.55 Million | -37.50% |
| 2015 | Skr973.68 Million | -- |
End of Day Market Cap According to Different Sources
On Jun 19th, 2026 the market cap of Karolinska Development AB ser. B was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $29.36 Million USD |
| MoneyControl | $29.36 Million USD |
| MarketWatch | $29.36 Million USD |
| marketcap.company | $29.36 Million USD |
| Reuters | $29.36 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Karolinska Development AB ser. B
KDventures AB is a venture capital firm specializing in investments in growth capital, seed stage, and early stage companies. It seeks to invest in pharmaceutical research and development, medical research, medical innovations, healthcare technology, gene research and development, drug delivery technologies, biotechnology, and life science tools and service sectors. The firm seeks to invest in th… Read more